Georgiana Toma: From Cytoreduction to Vascular Protection in Essential Thrombocythemia
Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:
“To my colleagues in internal medicine and neurology
We have all managed patients with ‘controlled’ platelet counts who still suffer from devastating recurrent strokes or systemic thrombotic events.
The results of the SURPASS-ET study (published in The Lancet Haematology, 2026) change the conversation from simple cytoreduction to vascular protection and disease modification.
Ropeginterferon alfa-2b
For our patients resistant to hydroxyurea, the comparison between Ropeginterferon alfa-2b and Anagrelide reveals a massive shift in the safety-efficacy balance:
- Vascular Risk: Complications (including cerebral infarction) were significantly lower with Ropeginterferon compared to Anagrelide.
- Safety Profile: Half the rate of Serious Adverse Events (14 percent versus 30 percent).
- Durable Response: A staggering 43 percent durable response at 12 months versus only 6 percent for anagrelide (p less than 0.0001).
Why this matters for your practice:
- Ropeginterferon significantly reduces the JAK2 (V617F) allelic burden. This suggests we can actually prevent the long-term transformation into Myelofibrosis or Acute Leukemia—something traditional therapies struggled to achieve.
- Neurological Protection: For Neurologists, this offers a potent tool to reduce the risk of cerebral infarction and hemorrhage in high-risk MPN patients.
- Fewer Side Effects: Better tolerability means higher compliance and fewer hospitalizations for drug-related complications.
The Bottom Line
We are moving toward a new standard where molecular remission is the goal.
By targeting the underlying biology of Myeloproliferative Neoplasms, we aren’t just treating a lab value; we are protecting our patients’ vascular future.”
Title: Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
Authors: Ruben Mesa, Harinder Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken-Hong Lim, Sung-Eun Lee, Sung Hwa Bae, Winnie Z Y Teo, Dawn Maze, Stephen T Oh, Prithviraj Bose, Toshiaki Sato, Zagrijtschuk, Sheena Lin, Weichung Joe Shih, John Mascarenhas, Lucia Masarova
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event